Role of aspirin in the prevention and treatment of colon cancer
The new study shows that aspirin may help prevent colon cancer, among other diseases. Patients already taking daily aspirin for heart benefits, it could even be done in other ways. Although it is not checked, there are several new studies show that aspirin may help prevent colon cancer. For patients who have had colon cancer, also shows that taking an aspirin a daytogether with their other prescribed treatments.
It 's too soon for the full recommendations of side effects of this form of therapy are still investigating, but may be a way that patients are able to help themselves is not. Two major studies are:
· Nurses Health Study
Health Professionals Follow-up · 'Study
It 'been fundamentally observational studies in which researchers found that patients were onlyalready do in their daily routine. The researchers followed almost 1,300 people over a period of 12 years. Many of the patients had surgery for colon cancer for long, and received chemotherapy for their disease.
Results
Of the patients who took aspirin regularly after their diagnosis, fell 15 percent. Among patients not taking aspirin on a daily basis after their diagnosis, approximately 19 percent are dead. Even with these findings, the researchers expect that other considerations such as family history. Overall it is estimated that aspirin may benefit patients with cancer of the colon in a reduction of 29 percent risk of death from disease.
Aspirin blocking an enzyme in the body and plants that seem to spread the cause of cancer. So now you see why it is possible that aspirin actually help patients diagnosed with colonCancer>.
Other tests
Robert M. Sandler, MD, one of the principal investigators in other studies, together with colleagues recruited about 1,100 patients with a history of polyps and another 635 patients with a history of colon cancer. Some patients received placebo and the other is a regular aspirin given day. The study was conducted over a period of three years, but was stopped early because there was substantial reductionvolume of polyps in patients undergoing treatment for the therapy prescribed aspirin rather than placebo.
Again, there is not enough information or evidence for aspirin for cancer, a board recommendation for patients of colon polyps or a history. In an attempt to Sandler, patients with other groups based in the dose of aspirin daily data. Patients taking placebo showed greater recurrencethan the other two groups, but the group that low doses of aspirin showed better results than those with the highest dose of aspirin on a daily basis. How is this possible? This is just one of many questions that researchers are still trying to answer.